270 related articles for article (PubMed ID: 26883333)
1. Added value of amide proton transfer imaging to conventional and perfusion MR imaging for evaluating the treatment response of newly diagnosed glioblastoma.
Park KJ; Kim HS; Park JE; Shim WH; Kim SJ; Smith SA
Eur Radiol; 2016 Dec; 26(12):4390-4403. PubMed ID: 26883333
[TBL] [Abstract][Full Text] [Related]
2. Histogram Analysis of Amide Proton Transfer Imaging to Identify Contrast-enhancing Low-Grade Brain Tumor That Mimics High-Grade Tumor: Increased Accuracy of MR Perfusion.
Park JE; Kim HS; Park KJ; Choi CG; Kim SJ
Radiology; 2015 Oct; 277(1):151-61. PubMed ID: 25910226
[TBL] [Abstract][Full Text] [Related]
3. Grading diffuse gliomas without intense contrast enhancement by amide proton transfer MR imaging: comparisons with diffusion- and perfusion-weighted imaging.
Togao O; Hiwatashi A; Yamashita K; Kikuchi K; Keupp J; Yoshimoto K; Kuga D; Yoneyama M; Suzuki SO; Iwaki T; Takahashi M; Iihara K; Honda H
Eur Radiol; 2017 Feb; 27(2):578-588. PubMed ID: 27003139
[TBL] [Abstract][Full Text] [Related]
4. Pre- and Posttreatment Glioma: Comparison of Amide Proton Transfer Imaging with MR Spectroscopy for Biomarkers of Tumor Proliferation.
Park JE; Kim HS; Park KJ; Kim SJ; Kim JH; Smith SA
Radiology; 2016 Feb; 278(2):514-23. PubMed ID: 26491847
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic performance between contrast enhancement, proton MR spectroscopy, and amide proton transfer imaging in patients with brain tumors.
Sakata A; Fushimi Y; Okada T; Arakawa Y; Kunieda T; Minamiguchi S; Kido A; Sakashita N; Miyamoto S; Togashi K
J Magn Reson Imaging; 2017 Sep; 46(3):732-739. PubMed ID: 28252822
[TBL] [Abstract][Full Text] [Related]
6. Which combination of MR imaging modalities is best for predicting recurrent glioblastoma? Study of diagnostic accuracy and reproducibility.
Kim HS; Goh MJ; Kim N; Choi CG; Kim SJ; Kim JH
Radiology; 2014 Dec; 273(3):831-43. PubMed ID: 24885857
[TBL] [Abstract][Full Text] [Related]
7. Uninterpretable Dynamic Susceptibility Contrast-Enhanced Perfusion MR Images in Patients with Post-Treatment Glioblastomas: Cross-Validation of Alternative Imaging Options.
Heo YJ; Kim HS; Park JE; Choi CG; Kim SJ
PLoS One; 2015; 10(8):e0136380. PubMed ID: 26296086
[TBL] [Abstract][Full Text] [Related]
8. Amide proton transfer imaging seems to provide higher diagnostic performance in post-treatment high-grade gliomas than methionine positron emission tomography.
Park JE; Lee JY; Kim HS; Oh JY; Jung SC; Kim SJ; Keupp J; Oh M; Kim JS
Eur Radiol; 2018 Aug; 28(8):3285-3295. PubMed ID: 29488086
[TBL] [Abstract][Full Text] [Related]
9. Amide proton transfer imaging to discriminate between low- and high-grade gliomas: added value to apparent diffusion coefficient and relative cerebral blood volume.
Choi YS; Ahn SS; Lee SK; Chang JH; Kang SG; Kim SH; Zhou J
Eur Radiol; 2017 Aug; 27(8):3181-3189. PubMed ID: 28116517
[TBL] [Abstract][Full Text] [Related]
10. Grading of Glioma: combined diagnostic value of amide proton transfer weighted, arterial spin labeling and diffusion weighted magnetic resonance imaging.
Kang XW; Xi YB; Liu TT; Wang N; Zhu YQ; Wang XR; Guo F
BMC Med Imaging; 2020 May; 20(1):50. PubMed ID: 32408867
[TBL] [Abstract][Full Text] [Related]
11. Different diagnostic values of imaging parameters to predict pseudoprogression in glioblastoma subgroups stratified by MGMT promoter methylation.
Yoon RG; Kim HS; Paik W; Shim WH; Kim SJ; Kim JH
Eur Radiol; 2017 Jan; 27(1):255-266. PubMed ID: 27048531
[TBL] [Abstract][Full Text] [Related]
12. Evaluating the Role of Amide Proton Transfer (APT)-Weighted Contrast, Optimized for Normalization and Region of Interest Selection, in Differentiation of Neoplastic and Infective Mass Lesions on 3T MRI.
Debnath A; Gupta RK; Singh A
Mol Imaging Biol; 2020 Apr; 22(2):384-396. PubMed ID: 31228076
[TBL] [Abstract][Full Text] [Related]
13. Grading glial tumors with amide proton transfer MR imaging: different analytical approaches.
Sakata A; Okada T; Yamamoto A; Kanagaki M; Fushimi Y; Okada T; Dodo T; Arakawa Y; Schmitt B; Miyamoto S; Togashi K
J Neurooncol; 2015 Apr; 122(2):339-48. PubMed ID: 25559689
[TBL] [Abstract][Full Text] [Related]
14. Pre-treatment amide proton transfer imaging predicts treatment outcome in nasopharyngeal carcinoma.
Qamar S; King AD; Ai QH; Mo FKF; Chen W; Poon DMC; Tong M; Ma BB; Yeung DK; Wang YX; Yuan J
Eur Radiol; 2020 Nov; 30(11):6339-6347. PubMed ID: 32588210
[TBL] [Abstract][Full Text] [Related]
15. Combination of IVIM-DWI and 3D-ASL for differentiating true progression from pseudoprogression of Glioblastoma multiforme after concurrent chemoradiotherapy: study protocol of a prospective diagnostic trial.
Liu ZC; Yan LF; Hu YC; Sun YZ; Tian Q; Nan HY; Yu Y; Sun Q; Wang W; Cui GB
BMC Med Imaging; 2017 Feb; 17(1):10. PubMed ID: 28143434
[TBL] [Abstract][Full Text] [Related]
16. Improved Differentiation of Low-Grade and High-Grade Gliomas and Detection of Tumor Proliferation Using APT Contrast Fitted from Z-Spectrum.
Zhang J; Zhu W; Tain R; Zhou XJ; Cai K
Mol Imaging Biol; 2018 Aug; 20(4):623-631. PubMed ID: 29313159
[TBL] [Abstract][Full Text] [Related]
17. True progression versus pseudoprogression in the treatment of glioblastomas: a comparison study of normalized cerebral blood volume and apparent diffusion coefficient by histogram analysis.
Song YS; Choi SH; Park CK; Yi KS; Lee WJ; Yun TJ; Kim TM; Lee SH; Kim JH; Sohn CH; Park SH; Kim IH; Jahng GH; Chang KH
Korean J Radiol; 2013; 14(4):662-72. PubMed ID: 23901325
[TBL] [Abstract][Full Text] [Related]
18. Prediction of pseudoprogression in post-treatment glioblastoma using dynamic susceptibility contrast-derived oxygenation and microvascular transit time heterogeneity measures.
Park JE; Kim HS; Kim N; Borra R; Mouridsen K; Hansen MB; Kim YH; Hong CK; Kim JH
Eur Radiol; 2024 May; 34(5):3061-3073. PubMed ID: 37848773
[TBL] [Abstract][Full Text] [Related]
19. Applying protein-based amide proton transfer MR imaging to distinguish solitary brain metastases from glioblastoma.
Yu H; Lou H; Zou T; Wang X; Jiang S; Huang Z; Du Y; Jiang C; Ma L; Zhu J; He W; Rui Q; Zhou J; Wen Z
Eur Radiol; 2017 Nov; 27(11):4516-4524. PubMed ID: 28534162
[TBL] [Abstract][Full Text] [Related]
20. Diagnostic Accuracy of T1-Weighted Dynamic Contrast-Enhanced-MRI and DWI-ADC for Differentiation of Glioblastoma and Primary CNS Lymphoma.
Lin X; Lee M; Buck O; Woo KM; Zhang Z; Hatzoglou V; Omuro A; Arevalo-Perez J; Thomas AA; Huse J; Peck K; Holodny AI; Young RJ
AJNR Am J Neuroradiol; 2017 Mar; 38(3):485-491. PubMed ID: 27932505
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
